Company profile: Ventus Therapeutics
1.1 - Company Overview
Company description
- Provider of novel small molecule medicines targeting the innate immune system to treat autoimmune and inflammatory diseases and cancer. Offers VENT-03, a first-in-class oral cGAS inhibitor in Phase 1; VENT-02, a brain-penetrant NLRP3 inhibitor in Phase 1 for neuro-inflammation and neurodegeneration; and ReSOLVE, a structural biology and computational chemistry platform for small molecule drug discovery.
Products and services
- ReSOLVE: Ventus architects a structure-guided platform combining structural biology and computational chemistry to identify and optimize small-molecule drugs
- VENT-02: Ventus develops a clinical-stage, brain-penetrant NLRP3 inhibitor in Phase 1 trials aimed at treating neuro-inflammation and neurodegeneration
- VENT-03: Ventus advances a first-in-class, clinical-stage cGAS inhibitor formulated for oral administration and currently undergoing Phase 1 clinical evaluation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ventus Therapeutics
Drug Delivery Experts
HQ: United States
Website
- Description: Provider of boutique drug product development services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Drug Delivery Experts company profile →
Cardinal Group
HQ: United States
Website
- Description: Provider of project management and building practitioner services and solutions focused on delivering pharmaceutical and biotechnology construction projects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardinal Group company profile →
Northeast Biolab
HQ: United States
Website
- Description: Provider of GLP and clinical bioanalysis services with 15+ years of experience, offering method development, validation and transfer; LC-MS bioanalysis; pharmacokinetics sample analysis and toxicokinetic safety testing; and assay platforms including ELISA, MSD, qPCR/ddPCR, Western Blot and In Cell Western for drug testing and biomarker analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northeast Biolab company profile →
Paragon Bioservices
HQ: United States
Website
- Description: Provider of contract development and manufacturing services for complex biopharmaceuticals, including AAV, oncolytic viruses, and next-generation vaccines. An industry-leading, private-equity backed CDMO focused on developing and manufacturing cutting-edge, transformative biopharmaceuticals and building strong client partnerships with the world's best biotech and pharma companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paragon Bioservices company profile →
Continuum Clinical
HQ: United States
Website
- Description: Provider of Health Economics and Outcomes Research services and clinical trial engagement solutions, including the MERIS Total Engagement suite for participant and site support with real-time performance data; patient recruitment campaigns; Global Site Solutions; study/site support; retention solutions; and patient advocacy and diversity & inclusion services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Continuum Clinical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ventus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ventus Therapeutics
2.2 - Growth funds investing in similar companies to Ventus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ventus Therapeutics
4.2 - Public trading comparable groups for Ventus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →